Presence of cell cycle pathway genes was found associated with significantly lower DMFS (log-rank P  = 0.0013), as well as higher hazard ratio (HR  = 9.71, 95% CI  = 3.3–28.6) in ER+ breast cancers, compared to tumors that lack this signature (Figure 2A). This evidence concerns the gene ESR1 and breast carcinoma.